Cboe UK • EUR Johnson & Johnson (JNJD.XC) Follow Compare 141.20 0.00 (0.00%) At close: January 8 at 10:43:26 AM GMT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for JNJD.XC 1D 5D 0.89% 1M -0.03% 3M -3.25% 6M 4.55% YTD 1.12% 1Y -0.28% 5Y -7.11% All -7.11% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: JNJD.XC View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Cramer on Johnson & Johnson (JNJ): A Value Trap Amid Lawsuits and Setbacks 4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025 FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab 2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid Contineum concludes enrolment in Phase II multiple sclerosis therapy trial How to Find Strong Medical Stocks Slated for Positive Earnings Surprises J&J Pauses Sales of Atrial Fibrillation Device, Stock Down Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis Johnson & Johnson MedTech pauses Varipulse rollout in US J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events